Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/17/2024 | $6.00 → $1.50 | Buy → Hold | Jefferies |
| 1/16/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 12/18/2023 | Mkt Perform → Outperform | William Blair | |
| 12/8/2023 | $9.00 → $6.00 | Buy | Jefferies |
| 9/27/2023 | $11.00 | Mkt Outperform | JMP Securities |
| 5/12/2023 | $6.00 → $9.00 | Hold → Buy | Jefferies |
| 3/7/2023 | $22.00 | Overweight | Piper Sandler |
| 9/12/2022 | $2.00 | Neutral → Underperform | SMBC Nikko |
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
4 - Allakos Inc. (0001564824) (Issuer)
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. "We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expertise will provide valuable insights as we continue to advance lirentelimab and our novel pipeline through clinical trials," said Robert Alexander, Ph.D., the Company's Chief Executive Officer. Dr. L
10-Q - Allakos Inc. (0001564824) (Filer)
8-K - Allakos Inc. (0001564824) (Filer)
8-K - Allakos Inc. (0001564824) (Filer)
Jefferies analyst Kevin Strang maintains Allakos (NASDAQ:ALLK) with a Hold and lowers the price target from $1.5 to $1.
JMP Securities analyst Jonathan Wolleben reiterates Allakos (NASDAQ:ALLK) with a Market Outperform and maintains $3 price target.
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
SC 13G/A - Allakos Inc. (0001564824) (Subject)
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results from the Phase 1 study of subcutaneous AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identi
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Completed dosing in the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers.Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results f
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple ascending Phase 1 study of intravenous (IV) AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been id
Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously
Cantor Fitzgerald downgraded Allakos from Overweight to Neutral
William Blair upgraded Allakos from Mkt Perform to Outperform
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m